<DOC>
	<DOCNO>NCT02906917</DOCNO>
	<brief_summary>Trial compare effect safety insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart subject type 2 diabetes treat basal insulin without oral antidiabetic treatment need treatment intensification .</brief_summary>
	<brief_title>A 38 Week Trial Comparing Effect Safety Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart Subjects With Type 2 Diabetes Treated With Basal Insulin With Without Oral Antidiabetic Treatment Need Treatment Intensification</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Male female , age least 18 year time signing informed consent Algeria : Male female , age least 19 year time signing informed consent Diagnosed type 2 diabetes mellitus Treated basal insulin least 90 day prior day screen Subject OAD ( ) prior trial participation OR subject stable daily dose ( ) OAD ( ) least 90 day prior screen visit ( V1 ) . The OAD ( ) include follow antidiabetic drug ) /regimen : a. Biguanides ( metformin least 1500 mg maximum tolerate dose document subject medical record ) b . Other OADs ( least half maximum approve dose accord local label maximum tolerate dose document subject medical record ) : i. Insulin secretagogues ( SU glinides ) ii . Dipeptidylpeptidase IV ( DPP4 ) inhibitor iii . Î±glucosidase inhibitor iv . Sodium/glucose cotransporter 2 ( SGLT2 ) inhibitor v. Oral combination product ( allow individual OADs ) HbA1c 7.010.0 % ( 5386 mmol/mol ) ( inclusive ) central laboratory analysis Body mass index ( BMI ) equal 45.0 kg/m^2 Participation clinical trial approve nonapproved investigational medicinal product within four week prior day screen ( V1 ) Any chronic disorder severe disease , opinion investigator , might jeopardise subject 's safety compliance protocol Acute decompensation glycaemic control require immediate intensification treatment prevent severe metabolic dysregulation ( e.g . diabetes ketoacidosis ) equal 90 day prior day screen screen randomisation Any following : myocardial infarction , stroke hospitalization unstable angina transient ischaemic attack within past 180 day prior day screen screen randomisation Renal impairment measure estimate Glomerular Filtration Rate ( eGFR ) value 60 ml/min/1.73 m^2 define KDIGO 2012 classification use isotope dilution mass spectrometry ( IDMS ) serum creatinine measure screening Impaired liver function , define alanine aminotransferase ( ALT ) equal 2.5 time upper normal limit ( UNL ) screening . Subjects presently classified New York Heart Association ( NYHA ) Class IV Planned coronary , carotid peripheral artery revascularisation know day screen Treatment medication indication diabetes obesity state inclusion criterion period 90 day day screen Anticipated initiation change concomitant medication ( 14 consecutive day ) know affect weight glucose metabolism ( e.g . treatment orlistat , thyroid hormone , corticosteroid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>